Like many successful companies, Clinically Relevant was founded when its founder realized he had a need that was not being met. Namely, he wanted to be able to quickly find out what the clinical evidence was for a particular diagnostic test. While the relevant papers could be found by performing a literature search, he figured there must be better way for a clinician on the move. Thus CORE or Clinical ORthopaedic Exam was born (iMedicalApps reviews: iPhone, Android ). In his regular job, Daniel Rhon, MPT, DPT, DSc is a research physical therapist at Madigan Army Medical Center in Seattle
The company went on to publish other successful apps. In addition to commercial success, the company now also garnering academic attention, with CORE being reviewed in one of the top physical therapy journals, The Journal of Orthopaedic & Sports Physical Therapy (JOSPT) (link – subscription required)
After their initial success on iOS with CORE and other titles, the company decided to port their apps to the Android platform. As one the first serious legitimate medical apps on Android, CORE was among the titles selected by Google to pre-populate the medical section of the Android Market as it initially launched in December 2010. Their most recent tile, a three app series titled Mobile OMT (Orthopedic Manipulative Therapy) has been released both on iOS and in Mac App store, providing now a unique opportunity to compare three different platforms and distribution channels.
As can be seen in the following interview, the challenges the Android Marketplace poses for the medical app developer are real, including the initially poorly implemented piracy controls, lack of promo codes and the size limits of the apps. In contrast, the more “managed” iTunes app store provided a more stable and predictable distribution channel, with less fear of piracy.
Sales were very slow at the beginning on Android, perhaps making them wonder whether the effort to port the apps could have been better invested into developing more features or apps on iOS. At least in that sense, it was heartening that the largest proportion of the required work was in curating the underlying clinical evidence, rather than in porting the coding to a second platform. Since then, however, sales on Android have steadily been picking up and the company is now even considering rebuilding their apps for the budding Android tablet market.